Matteo Monami1, Niccolò Marchionni, Edoardo Mannucci. 1. Section of Geriatric Cardiology, Department of Cardiovascular Medicine, Azienda Ospedaliero-Universitaria Careggi, Via delle Oblate 4, 50141 Florence, Italy.
Abstract
BACKGROUND: Long-acting insulin analogues, in comparison with NPH insulin, should warrant a greater reproducibility of absorption after subcutaneous injection, providing better metabolic control with reduced hypoglycaemic risk. Aim of the present meta-analysis is the assessment of differences with respect to HbA1c, incidence of hypoglycaemia, weight gain, between NPH human insulin and each long-acting analogue. METHODS: All randomized controlled trials (RCTs) with a duration >12 weeks comparing long-acting insulin analogues (detemir or glargine) with NPH insulin in type 2 diabetic patients were retrieved; data on HbA1c and BMI at endpoint, and incidence of any, symptomatic, nocturnal, and severe hypoglycaemia, were extracted and meta-analysed. RESULTS: A total of 14 RCTs was retrieved and included in the analysis. Long-acting analogues did not produce any significant improvement of HbA1c, in comparison with NPH human insulin. When trials with different analogues were analysed separately, NPH showed a significant superiority (by 0.1%) over detemir, but not over glargine. When analysing the effect of long-acting analogues on body weight, detemir, but not glargine, was associated with a significantly smaller weight gain than human insulin Both analogues were associated with a reduced risk for nocturnal and symptomatic hypoglycaemia (OR: 0.46[0.38-0.55] and 0.69[0.60-0.80]; all p<0.01). CONCLUSIONS: Long-acting insulin analogues in type 2 diabetic patients does not seem to provide a better glycemic control in comparison with NPH insulin, whereas it reduces the risk of nocturnal and symptomatic hypoglycemia. Detemir, but not glargine, could be associated with smaller weight gain than NPH insulin.
BACKGROUND: Long-acting insulin analogues, in comparison with NPH insulin, should warrant a greater reproducibility of absorption after subcutaneous injection, providing better metabolic control with reduced hypoglycaemic risk. Aim of the present meta-analysis is the assessment of differences with respect to HbA1c, incidence of hypoglycaemia, weight gain, between NPH humaninsulin and each long-acting analogue. METHODS: All randomized controlled trials (RCTs) with a duration >12 weeks comparing long-acting insulin analogues (detemir or glargine) with NPH insulin in type 2 diabeticpatients were retrieved; data on HbA1c and BMI at endpoint, and incidence of any, symptomatic, nocturnal, and severe hypoglycaemia, were extracted and meta-analysed. RESULTS: A total of 14 RCTs was retrieved and included in the analysis. Long-acting analogues did not produce any significant improvement of HbA1c, in comparison with NPH humaninsulin. When trials with different analogues were analysed separately, NPH showed a significant superiority (by 0.1%) over detemir, but not over glargine. When analysing the effect of long-acting analogues on body weight, detemir, but not glargine, was associated with a significantly smaller weight gain than humaninsulin Both analogues were associated with a reduced risk for nocturnal and symptomatic hypoglycaemia (OR: 0.46[0.38-0.55] and 0.69[0.60-0.80]; all p<0.01). CONCLUSIONS: Long-acting insulin analogues in type 2 diabeticpatients does not seem to provide a better glycemic control in comparison with NPH insulin, whereas it reduces the risk of nocturnal and symptomatic hypoglycemia. Detemir, but not glargine, could be associated with smaller weight gain than NPH insulin.
Authors: Monika Lechleitner; Martin Clodi; Heidemarie Abrahamian; Helmut Brath; Johanna Brix; Heinz Drexel; Peter Fasching; Bernhard Föger; Claudia Francesconi; Elke Fröhlich-Reiterer; Jürgen Harreiter; Sabine E Hofer; Friedrich Hoppichler; Joakim Huber; Susanne Kaser; Alexandra Kautzky-Willer; Bernhard Ludvik; Anton Luger; Julia K Mader; Bernhard Paulweber; Thomas Pieber; Rudolf Prager; Birgit Rami-Merhar; Michael Resl; Michaela Riedl; Michael Roden; Christoph H Saely; Christian Schelkshorn; Guntram Schernthaner; Harald Sourij; Lars Stechemesser; Harald Stingl; Hermann Toplak; Thomas C Wascher; Raimund Weitgasser; Yvonne Winhofer-Stöckl; Sandra Zlamal-Fortunat Journal: Wien Klin Wochenschr Date: 2019-05 Impact factor: 1.704
Authors: G Schernthaner; A H Barnett; D J Betteridge; R Carmena; A Ceriello; B Charbonnel; M Hanefeld; R Lehmann; M T Malecki; R Nesto; V Pirags; A Scheen; J Seufert; A Sjohölm; A Tsatsoulis; R DeFronzo Journal: Diabetologia Date: 2010-03-31 Impact factor: 10.122
Authors: Kees J Gorter; Floris Alexander van de Laar; Paul G H Janssen; Sebastian T Houweling; Guy E H M Rutten Journal: BMJ Clin Evid Date: 2012-10-11
Authors: Alan J Garber; Martin J Abrahamson; Joshua I Barzilay; Lawrence Blonde; Zachary T Bloomgarden; Michael A Bush; Samuel Dagogo-Jack; Michael B Davidson; Daniel Einhorn; W Timothy Garvey; George Grunberger; Yehuda Handelsman; Irl B Hirsch; Paul S Jellinger; Janet B McGill; Jeffrey I Mechanick; Paul D Rosenblit; Guillermo E Umpierrez; Michael H Davidson Journal: Endocr Pract Date: 2013 May-Jun Impact factor: 3.443